GSTM1 (Glutathione S-transferase mu 1)

Advancements such as next-generation sequencing and immunogenetics, which identify the relationship between HPV variants and host immune genes that modulate disease susceptibility, vaccine responsiveness, and progression patterns across various genetic backgrounds. This review systematically integrates molecular mechanisms of HPV variant-induced oncogenesis and host genetic susceptibility with emphasis on population-based variability in addition to evidence culled from meta-analyses and GWAS data for immune regulation, DNA repair, as well as host single nucleotide polymorphisms in different populations and its implications for personalized prevention measures, screening, and vaccine response.

P=N/A, N=48, Recruiting, University of British Columbia | Trial primary completion date: Aug 2027 --> Dec 2028

The findings suggest that the NAT2 WT/M3 polymorphism, along with smoking and UTDs, contributes to RCC susceptibility in Mongolian cases.

These findings provide novel insights into the transcriptional landscape of OSSN and identify key pathways that may be targeted for improved diagnosis and therapy. The molecular insights provided by this study can potentially inform stratified management approaches and aid in the development of novel treatments for this challenging ocular surface malignancy.

Null variants in GSTM1 and GSTT1 are linked to increased drug toxicity due to impaired detoxification. DNA repair gene variants, such as XRCC1 Arg399Gln and ERCC2 Lys751Gln, influence treatment response and risk of side effects.

This ML-based model using MRGs effectively predicts CRC prognosis, immune microenvironment, and therapeutic response, offering a framework for precision oncology. The 7-gene signature may guide risk stratification and targeted therapy, bridging mitochondrial biology with clinical outcomes.

Genotypes of GSTP1, GSTM1, and GSTT1 were analyzed in 185 gastric cancer patients receiving SOX/XELOX regimens. However, the combined GSTP1(AG+GG)/GSTM1- genotype was linked to an improved chemotherapy response and significantly better overall and progression-free survival. The GSTP1 genotype status could be a valuable predictive biomarker for treatment response and survival, potentially facilitating more personalized therapeutic approaches for gastric cancer.

Our findings support the feasibility of individualized lazertinib dosing based on GSTM1 status to reduce toxicity and healthcare costs without compromising effective exposure.

The GSTT1 T-- genotype was an independent predictor in the one- and five-year probabilities of both recurrence and progression of BC. GSTT1 rs17856199 may be a significant factor in the development of tumors and the course of disease in Bosnian and Herzegovinian BC patients.

This study elucidates the immune-related pathways influencing bladder cancer, highlighting GSTM1 and other key immune-related genes as potential biomarkers. These discoveries pave the way for innovative therapeutic approaches, advancing personalized medicine strategies in bladder cancer treatment.

A novel baseline response index combining CCL4 and pRb showed excellent predictive performance and stratified patients by likelihood of clinical benefit, with ctDNA dynamics further refining stratification. These findings support DAL-AI as a promising neoadjuvant option and highlight the value of biomarker-guided strategies for treatment optimization.

Overall, GSTM1 status affected lazertinib PK in healthy participants and hence further research is warranted to determine the magnitude of PK differences and whether they are clinically meaningful in the NSCLC patient population intended to be treated with lazertinib.